139 completed, 65 unknown, 56 recruiting, 46 terminated. 188 Phase 2, 148 Phase 1, 25 Phase 3, 17 Not applicable, 8 Early Phase 1.
Follow Lymphoma, T-Cell, Peripheral: new trials by email Literature Review of Lymphoma, T-Cell, Peripheral trials Research Report on Lymphoma, T-Cell, Peripheral
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-11-12 |
| Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38. GNTbm-38 - Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Not yet recruiting | Great Novel Therapeutics Biotech & Medicals Corporation | 70 | 2026-12-01 | 2026-09-25 |
| Allogeneic Cell Therapy in Refractory T-Cell Lymphoma Baseline FDG-PET/CT, First-line chemotherapy, Interim FDG-PET/CT after two cycles of first-line chemotherapy - Lymphoma, T Cell, Peripheral | Phase 2 | Not yet recruiting | University Medical Center Goettingen | 70 | 2026-11-01 | 2026-11-05 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma KK2223 - T-cell NHL (PTCL or CTCL) | Phase 1 | Recruiting | Kyowa Kirin, Inc. | 72 | 2026-09-02 | 2026-09-30 |
| The Efficacy of CAPCT in Patients With PTCL Chidamide, Azacitidine (AZA), Prednisone - Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 58 | 2026-08-01 | 2026-08-05 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| New Genotype-guided Treatment in Newly Diagnosed PTCL Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP - Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 108 | 2026-07-01 | 2026-07-16 |
| A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma. PTCL, T Cell Lymphoma | Not yet recruiting | Ruijin Hospital | 1000 | 2026-06-01 | 2026-06-18 | |
| Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma Adebrelimab & SHR2554 - Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 40 | 2026-05-29 | 2026-05-29 |
| Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma Anti-TRBC1 CAR-T cells - Refractory/Recurrent Peripheral T-cell Lymphoma | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-04-01 | 2026-03-17 |
| Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma Aclarubicin, Cyclophosphamide, Vincristine - Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma | Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 36 | 2026-03-30 | 2026-04-17 |
| Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma PET-CTandct- DNAdetection, golidocitinib, Placebo - Maintenance Treatment of Peripheral T-cell Lymphoma | Phase 3 | Recruiting | Fudan University | 136 | 2026-03-27 | 2026-03-31 |
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma azacitidine, abatacept - Lymphoma, T Cell, Peripheral, T-cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-03-26 | 2026-11-09 |
| Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 96 | 2026-03-02 | 2026-04-13 |
| Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain Brentuximab Vedotin Plus CHP - CD30-Positive Peripheral T-Cell Lymphoma | Recruiting | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 100 | 2026-02-15 | 2026-06-03 | |
| Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy golidocitinib, Placebo - Peripheral T Cell Lymphoma | Phase 3 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 68 | 2026-02-15 | 2026-02-24 |
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 44 | 2026-02-12 | 2026-10-27 |
| A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. BR101801 - Peripheral T Cell Lymphoma | Phase 2 | Not yet recruiting | Boryung Pharmaceutical Co., Ltd | 44 | 2026-02-01 | 2026-01-28 |
| A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma Cidabenamine, Azacitidine - Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 40 | 2026-02-01 | 2026-02-05 |
Showing 20 of 362. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (85) · Lymphoma, Large B-Cell, Diffuse (82) · Lymphoma, Large-Cell, Anaplastic (81) · Lymphoma, Non-Hodgkin (81) · Immunoblastic Lymphadenopathy (70) · Lymphoma, Extranodal NK-T-Cell (66) · Hodgkin Disease (64) · Leukemia, Lymphocytic, Chronic, B-Cell (63) · Lymphoma, Follicular (61) · Lymphoma, Mantle-Cell (58) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (58) · Recurrence (58) · Mycosis Fungoides (57) · Lymphoma, B-Cell, Marginal Zone (55)
Hemic and Lymphatic Diseases (362) · Immunoproliferative Disorders (362) · Lymphatic Diseases (361) · Neoplasms by Histologic Type (361) · Immune System Diseases (360) · Lymphoproliferative Disorders (357) · Neoplasms (356) · Lymphoma, T-Cell (323) · Lymphoma (314) · Lymphoma, Non-Hodgkin (281) · Pathologic Processes (110) · Pathological Conditions, Signs and Symptoms (110) · Disease Attributes (109) · Hematologic Diseases (108) · Leukemia, Lymphoid (98)
Cyclophosphamide (47) · Prednisone (33) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (31) · Vincristine (29) · Doxorubicin (28) · Etoposide (23) · romidepsin (20) · Gemcitabine (18) · Lenalidomide (16) · 10-propargyl-10-deazaaminopterin (15) · Azacitidine (15) · Whole-Body Irradiation (15) · fludarabine phosphate (15) · Brentuximab Vedotin (14) · Peripheral Blood Stem Cell Transplantation (14)
National Cancer Institute (NCI) (16) · Fred Hutchinson Cancer Center (14) · Ruijin Hospital (14) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (9) · Sun Yat-sen University (8) · Acrotech Biopharma Inc. (7) · Fudan University (6) · Institute of Hematology & Blood Diseases Hospital, China (5) · M.D. Anderson Cancer Center (5) · Peking Union Medical College Hospital (5) · Case Comprehensive Cancer Center (4) · Celgene (4) · Dizal Pharmaceuticals (4) · Kyowa Kirin Co., Ltd. (4) · The Lymphoma Academic Research Organisation (4)
United States (164) · China (106) · Italy (34) · France (28) · Spain (25) · South Korea (22) · Canada (20) · United Kingdom (20) · Japan (18) · Germany (17) · Australia (16) · Belgium (11) · Denmark (10) · Poland (9) · Taiwan (9)
David Maloney (4) · Ajay Gopal (3) · Brenda Sandmaier (3) · Ryan Wilcox, MD, PhD (3) · Weili Zhao (3) · Abhinav Deol, M.D. (2) · Andrei Shustov, MD (2) · Ann Woolfrey (2) · Barbara Pro, MD (2) · Beata Holkova, MD (2) · Daobin Zhou, MD (2) · Dehui Zou, Dr. (2)
PMID 32499241, PMID 25113753, PMID 31029646, PMID 33051668, PMID 1244564, PMID 16731764, PMID 18042692, PMID 18626005, PMID 18698002, PMID 19597183, PMID 19826128, PMID 19880495, PMID 19900571, PMID 20671118, PMID 21270441, PMID 21355097, PMID 21504290, PMID 21576639, PMID 22259028, PMID 22271479, PMID 23023715, PMID 23049383, PMID 23278639, PMID 23393050, PMID 23649469, PMID 23674495, PMID 23716537, PMID 23752175, PMID 23818604, PMID 24142051, PMID 24359243, PMID 24456586, PMID 24474568, PMID 24652992, PMID 24827808, PMID 25279222, PMID 25404094, PMID 25482745, PMID 25605368, PMID 25605745, PMID 25879747, PMID 25891346, PMID 26202875, PMID 26213141, PMID 26222726, PMID 26353084, PMID 26377597, PMID 26424652, PMID 26542718, PMID 26659919
P30CA015704 (12), 2023 (4), P01CA018029 (4), 2019 (2), P01CA078902 (2), P30CA016672 (2), P30CA036727 (2), P30CA043703 (2), P30CA072720 (2), U01CA097452 (2), U10CA021115 (2), 2008 (1), 2017 (1), 2025 (1), K12CA167540 (1)